Your browser doesn't support javascript.
loading
Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma.
König, David; Hench, Jürgen; Frank, Stephan; Dima, Laura; Bratic Hench, Ivana; Läubli, Heinz.
Afiliação
  • König D; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Hench J; Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Frank S; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Dima L; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Bratic Hench I; Bayer HealthCare Pharmaceuticals Inc., Basel, Switzerland.
  • Läubli H; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Pharmacology ; 107(7-8): 433-438, 2022.
Article em En | MEDLINE | ID: mdl-35526519
ABSTRACT
High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we describe a case of a patient with HGG with a previously unknown NTRK3 fusion that showed an extraordinary response to treatment with larotrectinib. This case supports regular testing for NTRK fusion proteins.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article